Development & Aid, Headlines, Health, North America

HEALTH: Genomic Advances Must Be Shared, Scientists Say

Katherine Stapp

NEW YORK, Oct 5 2001 (IPS) - With a genetic revolution anticipated in health care over the next decade, researchers are seeking to ensure that the benefits are not monopolised by the world’s wealthiest countries.

“Ninety percent of health research expenditure is for the health problems of 10 percent of the world’s population,” say University of Toronto scientists Peter Singer and Abdallah Daar say in a paper appearing in the Oct. 5 issue of Science magazine.

This chasm will only widen as medicine becomes increasingly high- tech, in large part thanks to the sequencing of the human genome last year, they warn in “Harnessing Genomics and Biotechnology to Improve Global Health Equity.”

“Everybody’s talking about the digital divide where information technology is widely used in Western countries but unavailable in developing countries,” says Singer, of the university’s Joint Centre for Bioethics.

“In health genomics, we’re now at a situation where we can prevent that divide from developing in the first place,” he said. “Those equity issues are some of the most important ethical questions facing the world today.”

The authors’ proposals include putting the issues of genomics and global health equity on the agenda of next year’s summit of the Group of Eight (G-8) industrialised countries in Kananaskis, Canada – something they stress would cost nothing and would be a key first step in establishing a political commitment.

Development of the biotech medical sector could be discussed partly in the context of funding for the New African Initiative, a comprehensive development plan for the continent. Eventually, a sustainable global investment fund could be established.

Specific examples of the benefits of new technology include using DNA probes to identify the parasitic disease leishmaniasis and dengue fever at the molecular level – a diagnostic tool already proven effective in Nicaragua, Ecuador and Guatemala.

When dengue fever unexpectedly exploded in Paraguay in early 2000, a local scientist named Leticia Franco was able to slow the epidemic in the capital, Asuncion, using advanced viral isolation techniques she had learned at the Sustainable Sciences Institute in San Francisco, the U.S. state of California.

The University of Nairobi in Kenya became a key partner in clinical trials for an AIDS vaccine that targets the strain most prevalent in Africa, after researchers noticed that some local prostitutes were not contracting HIV despite repeat exposures, apparently because their immune systems were able to fight off the virus.

Another broad avenue of research involves plant-based edible vaccines for hepatitis B, cholera, measles and human papilloma virus, which is associated with cervical cancer. Such oral vaccines do not require refrigeration and are cheaper than conventional vaccines, the authors note. A recombinant hepatitis B vaccine already has been introduced into potatoes and is now undergoing human trials.

While these examples mostly involve joint projects with wealthier countries, some developing countries have managed to create their own thriving biotech research industries, the authors point out.

Cuba, for example, holds more than 400 biotechnology patents and pioneered the world’s only vaccine for meningitis B.

India, an information technology powerhouse, has earmarked 85 million dollars for genomics research over the next five years and the Indian Institute of Technology in Delhi recently founded a School of Bioscience and Bioengineering. Indian researchers also are working on a vaccine for Plasmodium vivax, one of the four species of parasite that causes malaria in humans.

Analysing these successful models is critical, Singer says.

“We need to understand, for example, why Cuba, China and India have such strong biotechnology industries whereas neighbouring countries do not,” he and Daar write. “The lessons learned can be applied to build successful genomics and biotechnology industries in developing countries and to change the concept of genomics ‘for’ developing countries to one of genomics ‘by’ developing countries.”

In August, Singer and Daar attended the First Roundtable on Africa, Science and Technology in the Age of Globalisation, in Nairobi, where they met high-ranking science and technology officials from nearly a dozen African countries as well as other policy-makers and scientists.

The Roundtable, chaired by John Mugabe, director of the African Centre for Technology Studies in Nairobi, was a good starting point in mobilising local scientists to make this issue a priority for their own governments and the international community, Singer says.

Concrete first steps in building a global research and development network could include a G-8 task force along the lines of its Digital Opportunities Task Force, and eventually a global genomics commission, preferably chaired by a scientist from the developing world.

This last idea “needs some careful fine-tuning,” Singer said in a telephone interview. Essentially, it would act as a “platform for leaders from government, industry, NGOs (non-governmental organisations), academia and the public to come together.” Such dialogue, which he said has been largely absent in the controversial agricultural biotech revolution, “is crucial.”

The World Health Organisation also is preparing its own special report on genomics and world health, which it plans to release by the end of the year.

 
Republish | | Print |

Related Tags